LigaChem Biosciences KRX:141080KOSDAQ
리가켐바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, LigaChem Biosciences reported revenue of ₩5.5bn, down 83.0% year on year, and an operating loss of ₩72.0bn. LigaChem Biosciences (리가켐바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
LigaChem Biosciences quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩5.5bn | -83.0% | −₩72.0bn | −₩68.1bn |
| Q1 2026 | ₩35.9bn | -30.4% | −₩37.4bn | −₩33.3bn |
| Q4 2025 derived | ₩16.0bn | – | −₩73.1bn | −₩64.6bn |
| Q3 2025 | ₩41.4bn | – | −₩23.2bn | −₩15.3bn |
| Q2 2025 | ₩32.6bn | +6.1% | −₩21.5bn | −₩38.1bn |
| Q1 2025 | ₩51.6bn | +66.1% | ₩11.4bn | ₩26.5bn |
| Q4 2024 derived | – | – | −₩13.7bn | −₩5.4bn |
| Q3 2024 | – | – | ₩517m | ₩11.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
LigaChem Biosciences top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest LigaChem Biosciences news Korean headlines
No articles yet.